CAMBRIDGE, MASSACHUSETTS, 1 MARCH 2017—The MIT New Drug Development Paradigms Initiative (NEWDIGS) announced today that Hilary Malone, Chief Regulatory Officer for pharmaceutical company Sanofi, has joined the NEWDIGS Executive Committee. Sanofi is a strategic partner of NEWDIGS, which is an international, multi-stakeholder consortium to design modern systems that connect scientific discovery to patient care. In her role on the Executive Committee, Dr. Malone will help lead the initiative in its drive to advance the evolution of more adaptive approaches to biomedical innovation.
“NEWDIGS welcomes Dr. Malone to the Executive Committee,” said Dr. Gigi Hirsch, Executive Director of NEWDIGS and the MIT Center for Biomedical Innovation. “Her deep insights into the dynamic challenges and opportunities of drug development will greatly strengthen our ability to advance patient-centered innovation in ways that work for all stakeholders.
Dr. Malone, currently Head of Global Regulatory Affairs at Sanofi, has a strong record of bringing new therapies to market and navigating complex regulatory requirements and access challenges. Prior to joining Sanofi, Dr. Malone was Global Head of Regulatory Affairs at both Wyeth and Pfizer, where she led the regulatory organizations supporting all human health businesses: pharmaceuticals (biologicals, vaccines & small molecules), OTC brands, generics and infant nutritionals. She is also on the Board of Directors of Inhibikase Therapeutics.
“I’m excited to join the NEWDIGS Executive Committee, particularly at this critical juncture in the evolution of our global healthcare systems” said Dr. Malone. “The Committee brings together an insightful group of diverse leaders, and I look forward to collaborating with them and the NEWDIGS community to design and enact transformative new practices for biomedical innovation.”
About MIT NEWDIGS
MIT NEW Drug Development ParadIGmS (NEWDIGS) is an international “think and do tank” dedicated to helping biomedical innovation benefit all healthcare stakeholders faster and reliably. NEWDIGS designs, evaluates, and initiates advancements that are too complex and cross-cutting to be addressed by a single organization or market sector. Its members include global leaders in research, development, insurance, regulation, and patient advocacy. For more information, visit http://newdigs.mit.edu.